Boice C R, Freedman R S, Herson J, Wharton J T, Rutledge F N
Cancer. 1982 Jun 1;49(11):2242-5. doi: 10.1002/1097-0142(19820601)49:11<2242::aid-cncr2820491107>3.0.co;2-s.
Bleomycin and mitomycin-C (BLM-M) induction therapy was administered to 23 patients with recurrent squamous carcinoma of the uterine cervix. Six patients (26%) responded. Although these results are much lower than originally reported with BLM-M, there is statistical evidence that patients with disease outside the previous radiation therapy field have improved or more easily determined responses. There was no difference in survival between responders and nonresponders for patients who survived at least six weeks. Therapy was found to be relatively nontoxic with no deaths related to therapy.
对23例复发性子宫颈鳞状癌患者实施了博来霉素与丝裂霉素-C（BLM-M）诱导治疗。6例患者（26%）有反应。尽管这些结果远低于最初报道的BLM-M治疗结果，但有统计学证据表明，病变位于既往放疗野之外的患者反应有所改善或更易于判定。对于存活至少6周的患者，有反应者与无反应者的生存率无差异。发现该治疗相对无毒，无治疗相关死亡病例。
